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Abstract
Background Delayed recovery of gastrointestinal (GI)
motility is a common complication following surgery.
TZP-101/ulimorelin is a macrocyclic peptidomimetic
ghrelin receptor agonist with GI promotility effects that
signiﬁcantly accelerates time to recovery of GI motility
compared to placebo following partial colectomy. It is also
well tolerated. The objectives of this analysis were to
identify predictors of GI motility recovery in patients
undergoing partial colectomy and to evaluate whether these
factors affect ulimorelin acceleration of GI recovery.
Methods Covariate analysis assessed the effect of eight
variables—age, sex, body mass index, type of surgery
(right colectomy, left colectomy, other), duration of sur-
gery, blood loss, total opioid consumption, country—on
recovery of GI motility in 236 patients randomized to ul-
imorelin (n = 168) or placebo (n = 68). The primary
endpoint was the recovery of GI function (time from the
end of surgery to ﬁrst bowel movement). Stepwise
regression identiﬁed a parsimonious model of the smallest
subset of variables best predicting GI recovery.
Results Recovery was shorter for segmental/subtotal
colectomies vs. right colectomies (P = 0.016) and longer
with increased total opioid use (P = 0.037). The remaining
variables had no statistically signiﬁcant effect on GI
recovery. Effects of ulimorelin 480 lg/kg (the most
effective dose) on time to GI tract recovery remained sta-
tistically and clinically signiﬁcant (hazard ratio = 1.81,
P = 0.014) when adjusted for surgery type and/or total
opioid use.
Conclusions Two factors, type of surgery and total opioid
use, independently modiﬁed times to recovery of GI
motility following partial large bowel resection surgery.
Acceleration of recovery of GI motility by ulimorelin was
independent of these factors.
Introduction
Delayed recovery of gastrointestinal (GI) motility is com-
mon after surgery. It contributes to patient morbidity and
discomfort [1] and to increased health care costs [2].
Potential factors contributing to delayed recovery of GI
motility include physiological responses to surgical trauma
(e.g., endocrine responses; elaboration of endogenous
opioids and inﬂammatory cytokines [3]) as well as factors
related to perioperative care, such as general anesthesia and
opioid use [4]. Although the causative factor of delayed GI
recovery is the surgical procedure itself, the delay is often
exacerbated by perioperative opioid use. Opioid-based
regimens are common treatments for postsurgical pain
management; however, opioids bind to mu receptors in the
gut and can prolong the duration of GI recovery through
delayed gastric emptying, reduced GI motility, and dis-
rupted colonic myoelectric activity [5].
In addition, increased duration of surgery and blood loss
have been identiﬁed as risk factors for prolonged recovery
of GI motility following abdominal surgery [6]. In a cohort
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GI recovery occurred in 15.2%. The demographic factors
age and body mass index (BMI) were signiﬁcantly asso-
ciated with its incidence, whereas intraoperative features
(e.g., estimated blood loss, operating time, surgeon of
record) were not [7]. Similarly, Pikarsky et al. observed an
increased incidence of delayed GI recovery in obese
patients undergoing laparoscopic colorectal surgery versus
normal-weight patients [8]. The identiﬁcation of any
additional risk factors for delayed GI recovery following
surgery is relevant as it is currently not possible to predict
which patients will experience prolonged recovery of GI
motility following surgery.
Current strategies to accelerate recovery of GI motility
are aimed at ‘‘fast-track’’ or ‘‘enhanced-recovery’’ proto-
cols designed to reduce the impact of external and internal
factors on delayed GI function [9, 10]. The goal of these
protocols is to enable patients to recover earlier and
therefore go home sooner after surgery. A meta-analysis of
randomized controlled trials showed that fast-track proto-
cols can reduce the length of primary hospital stays [11].
However, data pooled from placebo arms of clinical trials
indicate that 34% of patients undergoing partial bowel
resection as part of standardized accelerated care pathways
were discharged from the hospital C7 days after surgery,
and more than 9% required a prolonged hospital stay or
readmission [12]. A 2008 Cochrane review concluded that
most drugs routinely used to enhance bowel recovery after
major abdominal surgery are not supported by current
research evidence [13], and an unmet need for effective
treatment remains.
Ulimorelin, a macrocyclic peptidomimetic ghrelin
receptor agonist with GI promotility effects, is in clinical
development for GI dysmotility disorders [14–19]. Ghrelin
is the natural ligand for growth hormone secretagogue
receptors (GHSR-1a), and both ghrelin and GHSR-1a are
co-localized in the proximal GI tract [20]. The ghrelin
receptor pathway mediates multiple GI functions, including
motility, gastric emptying, and induction of migrating
motor complexes (MMCs) [21]. This macrocyclic com-
pound represents the ﬁrst of a new class of ghrelin agonists
that does not duplicate any portion of the sequence of
ghrelin. Ulimorelin has enhanced metabolic stability and
high afﬁnity (Ki 22 nM) for the human type 1a GHSR
compared to ghrelin [22]. It has shown promotility activity
in animal models of GI dysmotility [14, 15] and in patients
with gastroparesis [16, 18].
Ulimorelin is well tolerated in healthy subjects and in
gastroparesis and postsurgical patients when administered
in daily doses ranging from 20 to 600 lg/kg [16–19].
Patients treated with ulimorelin doses of 20 to 600 lg/kg
following partial colectomy had signiﬁcantly accelerated
times to recovery of GI motility in all dose groups by
10–22 h versus placebo. Also, more patients who received
ulimorelin achieved recovery by 72 hours after surgery
compared to those given a placebo, resulting in an accel-
erated median time to readiness for hospital discharge
compared with the placebo group [19]. Based on the results
of this multicenter study in 236 patients undergoing treat-
ment, the most effective ulimorelin dose was identiﬁed as
480 lg/kg.[19] The two most common treatment-emergent
adverse events, nausea and vomiting, were reduced in the
ulimorelin group compared with the placebo group [19].
The ﬁrst objective of the present analysis was to identify
predictors of recovery of GI motility in patients undergoing
partial colectomy. The second aim was to evaluate whether
these factors affected ulimorelin acceleration of GI
recovery.
Methods
A multicenter, randomized, double-blind, placebo-con-
trolled, dose-ranging study was conducted from July 2007
to July 2008 at 29 sites: seven in the United States, nine in
Romania, nine in India, and four in Lithuania (Clinical
Trial Registry #NCT00617552). A full description of the
study methods and primary results has been previously
published [19]. The patients included were adult
(18–80 years) men and women with body weights B100 kg
scheduled to undergo open partial colectomy with primary
anastomosis, including segmental colon resection, right or
left hemicolectomy and subtotal colectomy. Patients were
scheduled to have available postoperative pain manage-
ment with intravenous opioids (including patient-controlled
analgesia) and enhanced-recovery, or ‘‘fast-track,’’ post-
operative care that included removal of the nasogastric tube
at the end of surgery, oral liquids and ambulation encour-
aged on postoperative day (POD) 1, and solid food offered
on POD 2. To obtain a relatively homogeneous patient
population, patients undergoing colostomy or ileostomy
creation, total colectomy, low anterior resection, surgery
for complete bowel obstruction, and laparoscopic proce-
dures were excluded [19].
Ulimorelin (20, 40, 80, 160, 320, 480, and 600 lg/kg) or
placebo was administered by intravenous infusion begin-
ning within 1 h after surgery and continued on a daily basis
until the ﬁrst bowel movement, hospital discharge, or POD
7, whichever came ﬁrst as previously described [19].
Internet-based or interactive voice response systems were
used for randomizing the ﬁrst 100 eligible patients in equal
numbers to receive daily intravenous infusions (60 ml/
30 min) of matching placebo or ulimorelin (20, 40, 80,
160, 320, 480, and 600 lg/kg) beginning within 1 h
of the conclusion of surgery. Subsequent participants
were assigned to treatment groups using an adaptive
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123randomization scheme with prospectively deﬁned alloca-
tion and decision rules. On a weekly basis, available study
data (time to ﬁrst bowel movement) were used to generate
a new randomization vector to determine dose allocation
for the next group of patients.
The primary endpoint was the recovery of GI function
deﬁned as the time from the end of surgery to ﬁrst bowel
movement (‘‘GI’’). A secondary endpoint (‘‘GI2’’) was
recovery of GI function deﬁned by the time from the end of
surgery to the later of the following two events: (1) time
that the patient ﬁrst tolerated solid food and (2) time that
the patient ﬁrst had a bowel movement—thereby evaluat-
ing both upper and lower GI recovery.
For this analysis, the potential effect of eight variables—
age,sex, bodymass index (BMI), type ofsurgery (right,left,
other),durationofsurgery(inhours),bloodloss,totalopioid
consumption, country—on postsurgical recovery of GI
motility in patients receiving ulimorelin versus placebo was
considered. Initially, stepwise proportional-hazard regres-
sion was used to identify parsimonious models of GI tract
recovery (a parsimonious model is one where the smallest
subset of variables adequately predicts the GI recovery
endpoints) across the total study population. Subsequently,
to determine whether any or all of these variables inﬂuenced
the effect of ulimorelinon recovery of GI motility, covariate
analysis was used to assess the ‘‘GI’’ and ‘‘GI2’’ endpoint
data (Cox proportional hazards model) for the ulimorelin
dose groups versus placebo. The Wald test was used to
calculate P values for the hazard ratios (HRs) of individual
ulimorelin dose levels relative to placebo and for the overall
signiﬁcance of the differences among all dose groups.
With respect to sample size, in Bayesian adaptively
randomized studies such as this one sample sizes can only
be estimated in advance, as the ongoing results determine
the ﬁnal number of patients enrolled in the study. This
study included a predeﬁned weekly automated Bayesian
analysis to determine the best performing doses and deﬁne
new weekly randomization schemes. Complete details are
described elsewhere [19].
Previous reporting of the primary endpoints from this
study identiﬁed the 480 lg/kg dose of ulimorelin as the
most effective one for improving recovery of GI motility
[19]. Therefore, results are presented for this dose relative
to placebo. Safety data for this study have been previously
analyzed and reported [19]. Adverse events occurring in
the placebo and the ulimorelin 480 lg/kg dose groups are
brieﬂy summarized in this report.
Results
A total of 236 randomized patients were dosed in the
United States (19 patients), Romania (129 patients), India
(75 patients), and Lithuania (13 patients). In all, 68
patients received placebo and 168 patients received
ulimorelin. Treatment groups were similar with respect to
demographic and baseline surgery characteristics (Table 1)
with the exception that a larger proportion of patients
receiving any ulimorelin dose were male (60%) compared
to patients receiving placebo (44%). The surgical resec-
tion procedures performed were predominantly right
hemicolectomy (106/236, 45%), segmental colon resec-
tion (75/236, 32%), and left hemicolectomy (44/236,
19%).
Total opioid [calculated as morphine equivalents (MEs)]
use per patient (n = 236) organized by country is shown in
Fig. 1. The total opioid use ranges were broad. The
medians (ranges) of total opioid use by patients receiving
Table 1 Summary demographics and baseline characteristics
Parameter Placebo All ulimorelin doses Ulimorelin 480 lg/kg
(n = 68) (n = 168) (n = 25)
Age (years), mean ± SD 55 ± 16 59 ± 15 60 ± 14
Sex (no.) (%)
Male 30 (44%) 101 (60%) 11 (44%)
Female 38 (56%) 67 (40%) 14 (56%)
Race (no.)
Asian 26 (38%) 48 (29%) 8 (32%)
African American 0 1 (0.6%) 0
White 42 (62%) 118 (70%) 17 (68%)
Other 0 1 (0.6%) 0
BMI (kg/m
2), mean ± SD 24.3 ± 4.07 23.9 ± 4.82 23.5 ± 4.97
Surgery duration (h), mean ± SD 2.5 ± 0.91 2.6 ± 1.08 2.5 ± 0.98
Anesthesia duration (h), mean ± SD 3.03 ± 1.04 3.13 ± 1.16 3.05 ± 1.08
Blood loss (ml), mean ± SD 243.43 ± 232.56 244.64 ± 202.22 258.4 ± 214.02
BMI body mass index
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123ulimorelin in the United States, Romania, Lithuania, and
India, respectively, were 170.8 (35–636.1), 104 (28–495),
136.2 (35–220), and 51.1 (10–289) MEs.
In an analysis of the entire study population, including
all doses and placebo (n = 236), two variables were
identiﬁed in the stepwise regression parsimonious model
(i.e., the model identifying the fewest covariates best pre-
dicting GI recovery). Their effects on recovery of GI
motility following partial large bowel resection surgery are
shown in Table 2. These two variables, surgery type and
total opioid use, had statistically signiﬁcant effects on both
‘‘GI’’ and ‘‘GI2’’ across the entire study population. The
results indicate that ‘‘GI’’ was signiﬁcantly shorter for
patients who underwent segmental or subtotal colectomy
than for those with a right hemicolectomy (P = 0.016).
Also, the ‘‘GI’’ was slightly longer with increased total
opioid use: For each additional 10 ME of opioids used,
recovery was delayed by 1% (P = 0.037). Similarly ‘‘GI2’’
was signiﬁcantly shorter for segmental and subtotal
colectomies than for right hemicolectomy (P = 0.044).
Also, ‘‘GI2’’ was slightly longer with increased total opioid
use: For each additional 10 ME of opioids used, recovery
was delayed by 1% (P = 0.007). The effects of the
remaining six variables on GI recovery were not statisti-
cally signiﬁcant in this analysis of the 236 patients.
Cox proportional hazard models for unadjusted and
variable-adjusted ulimorelin 480 lg/kg dose effects on GI
recovery are shown for ‘‘GI’’ and ‘‘GI2’’ endpoints in
Table 3. The ﬁrst row shows the hazard ratios and p values
for ulimorelin acceleration of GI recovery without adjust-
ment for any variable. As indicated in the Table 3, ulim-
orelin acceleration of GI recovery remained signiﬁcant
when adjusted for individual covariates for ‘‘GI’’ and all
but opioid use for ‘‘GI2’’ (although results trended toward
signiﬁcance) and when adjusting for all covariates. The
effects of adjusting for the two covariates identiﬁed in the
parsimonious model are shown in the last row of Table 3.
For ‘‘GI’’, the adjusted hazard ratio is numerically larger
and more signiﬁcant (HR = 1.81, P = 0.014) than the
unadjusted hazard ratios. For ‘‘GI2’’, the value of the
adjusted hazard ratio is the same as the unadjusted hazard
ratio (1.61) and approaches signiﬁcance (P = 0.06).
Figure 2 summarizes the shifts in hazard ratios when
adjusted for variables identiﬁed from the parsimonious
model.
Safety
Treatment emergent adverse events for the placebo and
ulimorelin 480 lg/kg group, shown in Table 4, are similar
to those previously reported for all the ulimorelin doses
combined [19]. Overall, the incidence of events was lower
Fig. 1 Total opioid use in morphine equivalents per patient organized
by country. Number of patients: United States, n = 19; Romania;
n = 129; Lithuania, n = 13; India, n = 75
Table 2 Effect of variables identiﬁed from stepwise proportional-
hazards regression (parsimonious model) across the total study pop-
ulation (n = 236)
Covariate Recovery
measure
Effect P
Surgery type ‘‘GI’’ Shorter for segmental/subtotal
versus right
0.016
‘‘GI2’’ 0.044
Total opioid
use
‘‘GI’’ Longer with increased opioid
use
0.037
‘‘GI2’’ 0.007
‘‘GI’’ primary endpoint; ‘‘GI2’’ secondary endpoint
Table 3 Effect of adjusting for variables, individually and combined,
on the ulimorelin impact on recovery of GI motility
Covariate ‘‘GI’’ HR ‘‘GI2’’ HR
Without adjustment
for any covariates
1.67 (0.029)
a 1.61 (0.044)
Country 1.63 (0.044) 1.61 (0.050)
Sex 1.70 (0.026) 1.64 (0.037)
Age 1.71 (0.027) 1.66 (0.037)
Weight 1.68 (0.028) 1.64 (0.038)
Duration of surgery 1.70 (0.024) 1.60 (0.048)
Blood loss 1.71 (0.025) 1.61 (0.047)
Surgery type 1.83 (0.012) 1.83 (0.013)
Total opioid use 1.63 (0.038) 1.56 (0.061)
Adjustment for all covariates
combined
1.73 (0.036) 1.67 (0.051)
Adjustment for two covariates
identiﬁed in parsimonious model:
total opioids and surgery type
1.81 (0.014) 1.61 (0.06)
Results are the hazard ratios for ulimorelin 480 lg/kg dose (n = 25)
versus placebo (n = 69) for the ‘‘GI’’ and ‘‘GI2’’ endpoints. HR
hazard ratio
a Numbers in parentheses are the p values
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123in the ulimorelin group (32%) than in the placebo group
(57%). Nausea and vomiting occurred frequently in the
placebo group but not in the ulimorelin group. Previous
reporting of safety data for the entire study that showed
time-averaged analysis of change from baseline for the
heart rate, PR interval, QRS, QT, and QTcB did not
identify dose-dependent changes or notable differences
from placebo [19]. Clinical or laboratory evaluations
showed no clinically relevant differences between ulimo-
relin and placebo-treated patients.
Discussion
Delayed recovery of GI motility following abdominal
surgery is a common occurrence. It is thought to involve
neural pathways, chemical mediators that vary depending
on the portion of the GI tract involved, and inﬂammatory
responses [23]. Identiﬁed risk factors for delayed recovery
of GI motility following surgery include opioid use and
more-invasive surgical procedures, but independent pre-
dictors of delayed GI tract recovery in patients have not
been well studied. A recent study identiﬁed the amount of
blood loss and total surgical time as independent predictors
of delayed recovery of GI motility following abdominal
surgery [6]. In this study, we examined potential predictors
of delayed recovery of GI motility in patients undergoing
partial colectomy and then assessed the efﬁcacy of the
ghrelin agonist ulimorelin when recovery times were
adjusted for the effects of these predictors.
Ulimorelin has previously been shown to have promo-
tility effects in patients with delayed GI motility, including
diabetes-associated gastroparesis [16, 18] and in patients
recovering from a partial colectomy [19]. Recovery of GI
motility after surgery can be delayed because of dysmotility
of the stomach or the small or large intestine. It has gen-
erally been thought that the small bowel normally resumes
activity several hours after surgery, the stomach 24–48 h
after surgery, and the colon 3–5 days after surgery [24].
Ghrelin has potent promotility action [21]. It has also
been shown to activate a cholinergic antiinﬂammatory
pathway, and this pathway may be a useful target in pre-
venting inﬂammatory cascades associated with postopera-
tive ileus [25]. Therefore, both the promotility and
antiinﬂammatory effects of ghrelin agonists may contribute
to recovery of GI motility after abdominal surgery. The
ghrelin agonist ulimorelin may have advantages over
peripheral opioid antagonists used in the management of
postoperative ileus (POI) as well as over other agents used
for dysmotility including erythromycin, dopamine antago-
nists, and cholecystokinin agonists, which have shown lack
1.5 2 2.5 0.5 0 3.0 1
Endpoint
1.67  1.73 1.81
1.61 1.67       
In favor of Ulimorelin In favor of Placebo
Fig. 2 Ulimorelin (480 lg/kg) (TZP-101) effects on gastrointestinal
(GI) recovery. Hazard ratios and conﬁdence intervals adjusted for
parsimonious model (white bars). For comparison, unadjusted (light
gray bars) and all adjustment (dark gray bars) hazard ratios are
shown. ‘‘GI’’: primary endpoint; ‘‘GI2’’: secondary endpoint. Note
that for ‘‘GI2,’’ the unadjusted and parsimonious models are both 1.61
Table 4 Treatment emergent adverse events occurring in C3% of
patients in the placebo and ulimorelin 480 lg/kg groups
Adverse event Placebo
(n = 68)
Ulimorelin 480 lg/kg
(n = 25)
Patients with at least
one TEAE
39 (57.4%) 8 (32.0%)
Nausea 18 (26.5%) 1 (4.0%)
Vomiting 11 (16.2%) 1 (4.0%)
Pyrexia 4 (5.8%) 0
Wound infection 3 (4.4%) 2 (8.0%)
Hypoalbuminemia 3 (4.4%) 0
Urinary tract infection 3 (4.4%) 0
Hypertension 2 (2.9%) 2 (8.0%)
Hyperglycemia 1 (1.5%) 1 (4.0%)
c-Glutamyltransferase increase 4 (5.9%) 0
Alanine aminotransferase
increase
4 (5.9%) 1 (4.0%)
Aspartate aminotransferase
increase
4 (5.9%) 1 (4.0%)
Hypoproteinemia 3 (4.4%) 0
TEAE treatment emergent adverse events
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recovery of GI tract motility after abdominal surgery [13].
Patients in the study undergoing partial colectomy
received enhanced-recovery, or ‘‘fast-track,’’ postoperative
care that included removal of nasogastric tubes at the end of
surgery, oral liquids, and ambulation encouraged on POD 1,
and solid food offered on POD 2. Under these conditions,
median times to ‘‘GI’’ and ‘‘GI2’’ in the placebo group were
90 and 91 h, respectively (*4 days), as previously reported
[19]. Ulimorelin (480 lg/kg) improved these times by 22
and 23 h, respectively, or by almost a full day [19].
In the present analysis, eight variables were assessed to
determine whether they were factors that inﬂuenced recov-
ery of GI motility in postsurgical patients. A stepwise
regressionalgorithmwasrun,andthevariableswereselected
by a stepwise algorithm as the most ‘‘parsimonious’’ model
(i.e.,themodelwiththefewesttermsneeded,inthesensethat
adding any extra covariates would not make the model
substantially better but removing any of the selected covar-
iates would make the model substantially worse). For the
‘‘GI’’ endpoint, the type of surgery and total opioid use were
thebestpredictors:Segmentalandsubtotalcolectomieswere
associatedwithshorterrecoverytimesrelativetorightpartial
colectomy; and greater total opioid use was associated with
longer recovery times. Similar associations were identiﬁed
for ‘‘GI2’’, indicating that recovery of both upper and lower
GI functions were similarly affected.
With the variables most inﬂuencing recovery time
identiﬁed, the regression analysis for the effect of ulimo-
relin on ‘‘GI’’ and ‘‘GI2’’ was adjusted for the effect of
these variables. Ulimorelin remained effective in decreas-
ing recovery times independent of the effect of the inﬂu-
encing covariates. When the model was adjusted for the
parsimonious variables that decreased (surgery type) or
increased recovery time (total opioid use), ulimorelin had a
greater numerical effect on time to recovery of the ‘‘GI’’
endpoint and greater statistical signiﬁcance than when
unadjusted for these two variables, whereas time to
recovery for ‘‘GI2’’ was unchanged.
We cannot conclude from our study that the duration of
surgery and blood loss were factors in recovery of GI
motility in the patient population studied, although there
was little variability in the duration of surgery or the
amount of blood lost. Segmental and subtotal colectomies
were associated with shorter recovery times than right
colectomy, with the recovery times for right and left co-
lectomies not statistically different. Not surprisingly, total
opioid use correlated with increased delay of GI recovery:
For each additional 10 ME of opioids used, GI recovery
was delayed by 1%.
Pharmacologic approaches to improving GI recovery
after surgery are limited [13]. Entereg is a peripherally
acting mu opioid antagonist approved in the United States
for accelerating GI recovery following partial large or
small bowel resection surgery with primary anastomosis.
Entereg did not show clinically signiﬁcant acceleration of
recovery in a study based in Europe, where patient-con-
trolled analgesia is not used as commonly as in the United
States [26]. In contrast, the mechanism of action of ulim-
orelin is opioid-independent. Patients in the present study
were enrolled in the United States, Europe, and Asia and
received a range of parenteral opioid doses (including
some via patient-controlled analgesia). Ulimorelin-related
improvements in GI tract recovery times persisted when
adjusted for opioid use, indicating that ulimorelin should
remain effective in improving time to recovery of GI
motility even when enhanced-recovery and opioid-sparing
pain management protocols are used.
Ulimorelin has a good safety and tolerability proﬁle
in patients with GI tract dysmotility [16, 18, 19]. In the
present analysis, safety proﬁles in the placebo and
ulimorelin group were consistent with those of other
patients undergoing abdominal surgery. Nausea and
vomiting, which were the most common treatment-
related adverse events in the placebo group, did not
occur in patients receiving the 480 lg/kg dose of
ulimorelin.
Conclusions
This analysis identiﬁed two factors, type of surgery and
total opioid use, that independently modiﬁed times to
recovery of GI motility following partial large bowel
resection surgery. Additionally, the acceleration of
recovery of GI motility by ulimorelin was independent
of these factors. The observation that opioid use did not
have a substantial impact on the effect of ulimorelin
underscores the opioid-independent mechanism of this GI
promotility agent and the potential utility of ulimorelin
in surgical GI recovery protocols that minimize opioid
use.
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